What we do

Our projects

The risk of getting Parkinson’s disease during one’s lifetime is now approximately 1:15 for anyone currently reading this website. (see Dorsey et al., The Emerging Evidence of the Parkinson Pandemic, Journal of Parkinson’s Disease 8 (2018) S3-S8, DOI 10.3233/JPD-181474)

Numbers based on a prospective study with more than 21.000 male participants. The key factor of influence is age. The value 1:15 (6,7%) is the median across all ages.
For more details see: Driver, J. et al.: Incidence and remaining lifetime risk of Parkinson disease in advanced age, Neurology

It is for this reason that the YUVEDO Foundation supports innovative research projects and organizes innovative digital and face-to-face events and projects, with the aim of achieving a causal therapy for PD.

Industry initiatives against neurodegenerative diseases (NDDs) are still insufficient. (see: https://yuvedofoundation.de/wp-content/uploads/2020/09/2020.09.16-NERA-Report-for-the-Yuvedo-Foundation.pdf).

In 2015 – 2016 alone, 32 new cancer therapies were FDA-approved in the US. Yet, over 2003 – 2016, no Alzheimer’s therapies were approved. How so?

Two key events initiated the global fight against cancer: The National Cancer Act of 1971 when the US declared ‚war on cancer‘, and The Human Genome Project of 1990 to map the human DNA. At least $100 billion has been invested to fight cancer over the past 40 years.
Industry initiatives against NDDs negligible, strongly suggesting market failure: current producers of NDD treatment drugs fail at producing a cure against NDDs (see: https://yuvedofoundation.de/wp-content/uploads/2020/09/2020.09.16-NERA-Report-for-the-Yuvedo-Foundation.pdf ).

A paradigm shift is needed and the fight against NDDs must begin in earnest. Since health risks are high and research on NDDs is lacking, state intervention is needed.

So WHY YUVEDO Foundation?

We create awareness.

We help persons with Parkinson’s or other NDD in need.

We advocate for more research and development and better treatment.

We conduct studies relevant for persons with Parkinson’s or other NDD.

We organize events for persons with Parkinson’s or other NDD.

As an example, the following diseases belong, inter alia, to the group of NDDs:

Parkinson’s disease

Alzheimer’s disease

Huntington’s disease

Amyotrophic lateral sclerosis (ALS)

For most NDDs there is still no cure. However, attempts are made to alleviate the resulting symptoms with medication or to supplement neurotransmitters whose release is impaired.